Compare Oxford Lane Capital Corp (OXLC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Oxford Lane Capital Corp trades at $8.85 (market cap $861.22M), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: Oxford Lane Capital Corp pays a 27.21% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Oxford Lane Capital Corp nearer its low. Which is the better fit depends on your goals.
| OXLC | XBI | |
|---|---|---|
Market Cap | $861.22M | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $19.90 | $164.28 |
52-Week Low | $8.15 | $85.16 |
Dividend Yield | 27.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.87, up 1.14% today, but faces a bearish technical outlook with significant selling pressure. The company reported a net income of $48.46 million for 2025, but recent quarterly earnings have consistently missed expectations, including a substantial miss in Q1 2026. Despite a high dividend yield, financial performance shows strain with negative ROE and ROA, while cash flow is heavily dependent on financing activities.
The outlook is cautious due to deteriorating fundamentals, negative profitability metrics, and bearish analyst sentiment. The primary opportunity lies in the high dividend yield, but risks include unsustainable distributions, declining net asset value, and potential for further earnings volatility. Investor caution is warranted given the conflicting signals between dividend income and underlying financial health.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
